Increased penetration of paclitaxel into the brain by inhibition of P-glycoprotein

Clinical Cancer Research

Volumn 9, Issue 7, 2003, Pages 2849-2855

  Kemper, E Marleen ^a   Van Zandbergen, A Erik ^a   Cleypool, Cindy ^a   Mos, Henk A ^b   Boogerd, Willem ^a,c   Beijnen, Jos H ^a,c,d   Van Tellingen, Olaf ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b GLAXOSMITHKLINE   (Netherlands)

^c SLOTERVAART HOSPITAL   (Netherlands)

^d UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CREMOPHOR; CYCLOSPORIN A; ELACRIDAR; GLYCOPROTEIN P; PACLITAXEL; PROTEIN INHIBITOR; VALSPODAR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN; BRAIN TUMOR; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG INHIBITION; DRUG LIVER LEVEL; DRUG PENETRATION; DRUG SELECTIVITY; DRUG UPTAKE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR MODEL; WILD TYPE;

ACRIDINES; ANIMALS; AREA UNDER CURVE; BLOOD-BRAIN BARRIER; BRAIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CLINICAL TRIALS; CYCLOSPORINE; CYCLOSPORINS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLYCEROL; MICE; MICE, KNOCKOUT; P-GLYCOPROTEIN; PACLITAXEL; TETRAHYDROISOQUINOLINES; TIME FACTORS;

EID: 0037478891     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. De Boer, A. G., and Breimer, D. D. Reconstitution of the blood-brain barrier in cell culture for studies of drug transport and metabolism. Adv. Drug Delivery Rev., 22: 251-264, 1996.
2. Levin, V. A. Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. J. Med. Chem., 23: 682-684, 1980.
3. Seelig, A., Gottschlich, R., and Devant, R. M. A method to determine the ability of drugs to diffuse through the blood-brain barrier. Proc. Natl. Acad. Sci. USA, 91: 68-72, 1994.
4. Cordon-Cardo, C., O'Brien, J. P., Casals, D., Rittman-Grauer, L., Biedler, J. L., Melamed, M. R., and Bertino, J. R. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc. Natl. Acad. Sci. USA, 86: 695-698, 1989.
5. Toth, K., Vaughan, M. M., Peress, N. S., Slocum, H. K., and Rustum, Y. M. MDR1 P-glycoprotein is expressed by endothelial cells of newly formed capillaries in human gliomas but is not expressed in the neovasculature of other primary tumors. Am. J. Pathol., 149: 853-858, 1996.
6. Beaulieu, E., Demeule, M., Ghitescu, L., and Beliveau, R. P-glycoprotein is strongly expressed in the luminal membranes of the endothelium of blood vessels in the brain. Biochem. J., 326: 539-544, 1997.
7. Kartner, N., Riordan, J. R., and Ling, V. Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science (Wash. DC), 221: 1285-1288, 1983.
8. Cordon-Cardo, C., O'Brien, J. P., Boccia, J., Casals, D., Bertino, J. R., and Melamed, M. R. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J. Histochem. Cytochem., 38: 1277-1287, 1990.
9. Schinkel, A. H., Smit, J. J., van Tellingen, O., Beijnen, J. H., Wagenaar, E., van Deemter, L., Mol, C. A., van der Valk, M. A., Robanus-Maandag, E. C., te Riele, H. P., and Borst, P. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell, 77: 491-502, 1994.
10. Schinkel, A. H., Wagenaar, E., Mol, C. A. A. M., and van Deemter, L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J. Clin. Investig., 97: 2517-2524, 1996.
11. van Asperen, J., Schinkel, A. H., Beijnen, J. H., Nooijen, W. J., Borst, P., and van Tellingen, O. Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient Mice. J. Natl. Cancer Inst. (Bethesda), 88: 994-999, 1996.
12. Arboix, M., Paz, O. G., Colombo, T., and Dincalci, M. Multidrug resistance-reversing agents increase vinblastine distribution in normal tissues expressing the P-glycoprotein but do not enhance drug penetration in brain and testis. J. Pharmacol. Exp. Ther., 281: 1226-1230, 1997.
13. Naito, M., and Tsuruo, T. New multidrug-resistance-reversing drugs, MS-209 and SDZ PSC 833. Cancer Chemother. Pharmacol., 40: S20-S24, 1997.
14. Hyafil, F., Vergely, C., Du Vignaud, P., and Grand-Perret, T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res., 53: 4595-4602, 1993.
15. Huizing, M. T., Misser, V. H., Pieters, R. C., ten Bokkel Huinink, W. W., Veenhof, C. H. N., Vermorken, J. B., Pinedo, H. M., and Beijnen, J. H. Taxanes: a new class of antitumor agents. Cancer Investig., 13: 381-404, 1995.
16. Rowinsky, E. K., and Donehower, R. C. Paclitaxel (Taxol). N. Engl. J. Med., 332: 1004-1014, 1995.
17. Prados, M. D., Schold, S. C., Spence, A. M., Berger, M. S., Mcallister, L. D., Mehta, M. P., Gilbert, M. R., Fulton, D., Kuhn, J., Lamborn, K., Rector, D. J., and Chang, S. M. Phase II study of paclitaxel in patients with recurrent malignant glioma. J. Clin. Oncol., 14: 2316-2321, 1996.
18. Huizing, M. T., Sparreboom, A., Rosing, H., van Tellingen, O., Pinedo, H. M., and Beijnen, J. H. Quantification of paclitaxel metabolites in human plasma by high-performance liquid chromatography. J. Chromatogr. B, 674: 261-268, 1995.
19. van Tellingen, O., Kemper, M., Tijssen, F., van Asperen, J., Nooijen, W. J., and Beijnen, J. H. High-performance liquid chromatographic bio-analysis of PSC 833 in human and murine plasma. J. Chromatogr. B, 719: 251-257, 1998.
20. Kemper, E. M., Jansen, B., Brouwer, K. R., Schellens, J. H. M., Beijnen, J. H., and van Tellingen, O. Bioanalysis and preliminary pharmacokinetics of the acridonecarboxamide derivative GF120918 in plasma of mice and humans by ion-pairing reversed-phase high-performance liquid chromatography with fluorescence detection. J. Chromatogr. B, 759: 135-143, 2001.
21. Sparreboom, A., van Tellingen, O., Huizing, M. T., Nooijen, W. J., and Beijnen, J. H. Determination of polyoxyethyleneglycerol triricinoleate 35 (Cremophor EL) in plasma by pre-column derivatization and reversed-phase high-performance liquid chromatography. J. Chromatogr. B, 681: 355-362, 1996.
22. Bardelmeijer, H. A., Beijnen, J. H., Brouwer, K. R., Rosing, H., Nooijen, W. J., Schellens, J. H., and van Tellingen, O. Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein. Clin. Cancer Res., 6: 4416-4421, 2000.
23. Mayer, U., Wagenaar, E., Dorobek, B., Beijnen, J. H., Borst, P., and Schinkel, A. H. Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833. J. Clin. Investig., 100: 2430-2436, 1997.
24. Drion, N., Lemaire, M., Lefauconnier, J. M., and Scherrmann, J. M. Role of P-glycoprotein in the blood-brain transport of colchicine and vinblastine. J. Neurochem., 67: 1688-1693, 1996.
25. Letrent, S. P., Pollack, G. M., Brouwer, K. R., and Brouwer, K. L. R. Effect of GF120918, a potent P-glycoprotein inhibitor, on morphine pharmacokinetics and pharmacodynamics in the rat. Pharm. Res. (N. Y.), 15: 599-605, 1998.
26. Slater, L. M., Sweet, P., Stupecky, M., Wetzel, M. W., and Gupta, S. Cyclosporin A corrects daunorubicin resistance in Ehrlich ascites carcinoma. Br. J. Cancer, 54: 235-238, 1986.
27. Slater, L. M., Cho, J., and Wetzel, M. Cyclosporin A potentiation of VP-16: production of long-term survival in murine acute lymphatic leukemia. Cancer Chemother. Pharmacol., 31: 53-56, 1992.
28. Meerum Terwogt, J. M., Beijnen, J. H., ten Bokkel Huinink, W. W., Rosing, H., and Schellens, J. H. M. Co-administration of cyclosporin enables oral therapy with paclitaxel. Lancet, 352: 285, 1998.
29. Hendrikse, N. H., Schinkel, A. H., de Vries, E. G., Fluks, E., van der Graaf, W. T., Willemsen, A. T., Vaalburg, W., and Franssen, E. J. Complete in vivo reversal of P-glycoprotein pump function in the blood-brain barrier visualized with positron emission tomography. Br. J. Pharmacol., 124: 1413-1418, 1998.
30. Malingré, M. M., Beijnen, J. H., Rosing, H., Koopman, F. J., Jewell, R. C., Paul, E. M., Huinink, W. W., and Schellens, J. H. M. Coadministration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients. Br. J. Cancer, 84: 42-47, 2001.
31. Sparreboom, A., van Asperen, J., Mayer, U., Schinkel, A. H., Smit, J. W., Meijer, D. K. F., Borst, P., Nooijen, W. J., Beijnen, J. H., and van Tellingen, O. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc. Natl. Acad. Sci. USA, 94: 2031-2035, 1997.
32. Walle, T., Walle, U. K., Kumar, G. N., and Bhalla, K. N. Taxol metabolism and disposition in cancer patients. Drug Metab. Dispos., 23: 506-512, 1995.
33. Rowinsky, E. K., Smith, L., Wang, Y. M., Chaturvedi, P., Villalona, M., Campbell, E., Aylesworth, C., Eckhardt, S. G., Hammond, L., Kraynak, M., Drengler, R., Stephenson, J., Harding, M. W., and Vonhoff, D. D. Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP. J. Clin. Oncol., 16: 2964-2976, 1998.
34. Boniface, G. R., Ferry, D., Atsmon, J., Inbar, M., van Tellingen, O., Abraham, J., Bates, S. E., Fojo, T., Thomas, H., Mould, G., Steiner, J., and Mellows, G. XR9576 (tariquidar), a potent and specific P-glycoprotein inhibitor, has minimal effects on the pharmacokinetics of paclitaxel, doxorubicin, and vinorelbine and can be administered with full-dose chemotherapy in patients with cancer. Proc. Am. Soc. Clin. Oncol., 39: 2173, 2002.
35. Fracasso, P. M., Westerveldt, P., Fears, C. A., Rosen, D. M., Zuhowski, E. G., Cazenave, L. A., Litchman, M., and Egorin, M. J. Phase I study of paclitaxel in combination with a multidrug resistance modulator, PSC 833 (Valspodar), in refractory malignancies. J. Clin. Oncol., 18: 1124-1135, 2000.
36. van Tellingen, O., Huizing, M. T., Panday, V. R., Schellens, J. H., Nooijen, W. J., and Beijnen, J. H. Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients. Br. J. Cancer, 81: 330-335, 1999.
37. Sparreboom, A., van Zuylen, L., Brouwer, E., Loos, W. J., Debruijn, P., Gelderblom, B., Pillay, M., Nooter, K., Stoter, G., and Verweij, J. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res., 59: 1454-1457, 1999.
38. Woodcock, D. M., Jefferson, S., Linsenmeyer, M. E., Crowther, P. J., Chojnowski, G. M., Williams, B., and Bertoncello, I. Reversal of the multidrug resistance phenotype with cremophor EL, a common vehicle for water-insoluble vitamins and drugs. Cancer Res., 50: 4199-4203, 1990.
39. Nygren, P., Csoka, K., Jonsson, B., Fridborg, H., Bergh, J., Hagberg, H., Glimelius, B., Brodin, O., Tholander, B., Kreuger, A., and Larsson, R. The cytotoxic activity of Taxol in primary cultures of tumour cells from patients is partly mediated by Cremophor EL. Br. J. Cancer, 71: 478-481, 1995.
40. Watanabe, T., Nakayama, Y., Naito, M., Ohhara, T., Itoh, Y., and Tsuruo, T. Cremophor EL reversed multidrug resistance in vitro but not in tumor-bearing mouse models. Anti-Cancer Drugs, 7: 825-832, 1996.